Design and characterization of valsartan Co-crystals to improve its aqueous solubility and dissolution behavior

Research output: Contribution to journalArticle

Abstract

The aim of the work was to prepare co-crystals of valsartan, a BCS Class II drug to enhance its aqueous solubility and bioavailability. The solvent evaporation method was used to prepare co-crystals by using different co-formers and varying the drug to co-former molar ratios. Succinic acid was found to be suitable co-former to prepare co-crystals with good physico-chemical properties. The solid state characterization of co-crystals were studied by FTIR, DSC and XRD. The co-crystals were evaluated for the saturation solubility and dissolution studies. Solubility study in distilled water indicated low solubility of valsartan (198.5 μg/ml), there was 2.6 fold increase in the solubility of co-crystals prepared using succinic acid, with 1:5 drug to co-former ratio (520.6 μg/ml). Solid state characterizations indicated there was no change in the chemical nature of the co-crystals compared to pure drug. Presence of crystalline co-former induced crystallinity to the developed co-crystals. Thus developed co-crystals were found to be suitable alternative to increase the solubility and dissolution rate of valsartan.

Original languageEnglish
Pages (from-to)26-30
Number of pages5
JournalResearch Journal of Pharmacy and Technology
Volume10
Issue number1
DOIs
Publication statusPublished - 2017

Fingerprint

Valsartan
Solubility
Succinic Acid
Pharmaceutical Preparations
Fourier Transform Infrared Spectroscopy
Biological Availability

All Science Journal Classification (ASJC) codes

  • Pharmacology, Toxicology and Pharmaceutics (miscellaneous)
  • Pharmacology (medical)

Cite this

@article{6390dfd577834a439a55cfed82d10627,
title = "Design and characterization of valsartan Co-crystals to improve its aqueous solubility and dissolution behavior",
abstract = "The aim of the work was to prepare co-crystals of valsartan, a BCS Class II drug to enhance its aqueous solubility and bioavailability. The solvent evaporation method was used to prepare co-crystals by using different co-formers and varying the drug to co-former molar ratios. Succinic acid was found to be suitable co-former to prepare co-crystals with good physico-chemical properties. The solid state characterization of co-crystals were studied by FTIR, DSC and XRD. The co-crystals were evaluated for the saturation solubility and dissolution studies. Solubility study in distilled water indicated low solubility of valsartan (198.5 μg/ml), there was 2.6 fold increase in the solubility of co-crystals prepared using succinic acid, with 1:5 drug to co-former ratio (520.6 μg/ml). Solid state characterizations indicated there was no change in the chemical nature of the co-crystals compared to pure drug. Presence of crystalline co-former induced crystallinity to the developed co-crystals. Thus developed co-crystals were found to be suitable alternative to increase the solubility and dissolution rate of valsartan.",
author = "Thomas, {Jino Elsa} and Nayak, {Usha Y.} and Jagadish, {P. C.} and Koteshwara, {K. B.}",
year = "2017",
doi = "10.5958/0974-360X.2017.00007.5",
language = "English",
volume = "10",
pages = "26--30",
journal = "Research Journal of Pharmacy and Technology",
issn = "0974-3618",
publisher = "A and V Publication",
number = "1",

}

TY - JOUR

T1 - Design and characterization of valsartan Co-crystals to improve its aqueous solubility and dissolution behavior

AU - Thomas, Jino Elsa

AU - Nayak, Usha Y.

AU - Jagadish, P. C.

AU - Koteshwara, K. B.

PY - 2017

Y1 - 2017

N2 - The aim of the work was to prepare co-crystals of valsartan, a BCS Class II drug to enhance its aqueous solubility and bioavailability. The solvent evaporation method was used to prepare co-crystals by using different co-formers and varying the drug to co-former molar ratios. Succinic acid was found to be suitable co-former to prepare co-crystals with good physico-chemical properties. The solid state characterization of co-crystals were studied by FTIR, DSC and XRD. The co-crystals were evaluated for the saturation solubility and dissolution studies. Solubility study in distilled water indicated low solubility of valsartan (198.5 μg/ml), there was 2.6 fold increase in the solubility of co-crystals prepared using succinic acid, with 1:5 drug to co-former ratio (520.6 μg/ml). Solid state characterizations indicated there was no change in the chemical nature of the co-crystals compared to pure drug. Presence of crystalline co-former induced crystallinity to the developed co-crystals. Thus developed co-crystals were found to be suitable alternative to increase the solubility and dissolution rate of valsartan.

AB - The aim of the work was to prepare co-crystals of valsartan, a BCS Class II drug to enhance its aqueous solubility and bioavailability. The solvent evaporation method was used to prepare co-crystals by using different co-formers and varying the drug to co-former molar ratios. Succinic acid was found to be suitable co-former to prepare co-crystals with good physico-chemical properties. The solid state characterization of co-crystals were studied by FTIR, DSC and XRD. The co-crystals were evaluated for the saturation solubility and dissolution studies. Solubility study in distilled water indicated low solubility of valsartan (198.5 μg/ml), there was 2.6 fold increase in the solubility of co-crystals prepared using succinic acid, with 1:5 drug to co-former ratio (520.6 μg/ml). Solid state characterizations indicated there was no change in the chemical nature of the co-crystals compared to pure drug. Presence of crystalline co-former induced crystallinity to the developed co-crystals. Thus developed co-crystals were found to be suitable alternative to increase the solubility and dissolution rate of valsartan.

UR - http://www.scopus.com/inward/record.url?scp=85014297108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85014297108&partnerID=8YFLogxK

U2 - 10.5958/0974-360X.2017.00007.5

DO - 10.5958/0974-360X.2017.00007.5

M3 - Article

VL - 10

SP - 26

EP - 30

JO - Research Journal of Pharmacy and Technology

JF - Research Journal of Pharmacy and Technology

SN - 0974-3618

IS - 1

ER -